HLS Therapeutics (TSX:HLS) Future 3-5Y EPS without NRI Growth Rate : 39.76 (As of May. 17, 2025)

View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, HLS Therapeutics's Future 3-5Y EPS without NRI Growth Rate is 39.76.

Competitive Comparison of HLS Therapeutics's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLS Therapeutics's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

HLS Therapeutics (TSX:HLS) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

HLS Therapeutics Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

HLTRF:USA

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W 6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.

Executives

Norma Beauchamp	Director
Jr. John Lee Welborn	Director
Craig Millian	Director, Senior Officer
Brian Thomas Walsh	Senior Officer
Polar Asset Management Partners Inc.	10% Security Holder
John Gordon Hanna	Director, Senior Officer
Athyrium Opportunities Ii Co-invest 1 Lp	10% Security Holder
Tim Hendrickson	Senior Officer
William M. Wells	Director, Senior Officer
Gilbert Godin	Director, Senior Officer
Gregory David Gubitz	Director
Orbimed Advisors Llc	10% Security Holder
Jason Gross	Senior Officer
Ryan Christopher Lennox	Senior Officer

HLS Therapeutics Headlines

No Headlines